Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) FCF Margin (2022 - 2025)

Arcutis Biotherapeutics has reported FCF Margin over the past 4 years, most recently at 20.86% for Q4 2025.

  • For Q4 2025, FCF Margin rose 2194.0% year-over-year to 20.86%; the TTM value through Dec 2025 reached 1.71%, up 5602.0%, while the annual FY2025 figure was 1.7%, 6573.0% up from the prior year.
  • FCF Margin for Q4 2025 was 20.86% at Arcutis Biotherapeutics, up from 1.77% in the prior quarter.
  • Over five years, FCF Margin peaked at 20.86% in Q4 2025 and troughed at 9338.07% in Q3 2022.
  • A 4-year average of 1200.09% and a median of 112.02% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: surged 919124bps in 2023 and later soared 1522bps in 2025.
  • Year by year, FCF Margin stood at 2404.19% in 2022, then soared by 83bps to 415.87% in 2023, then soared by 100bps to 1.08% in 2024, then soared by 2035bps to 20.86% in 2025.
  • Business Quant data shows FCF Margin for ARQT at 20.86% in Q4 2025, 1.77% in Q3 2025, and 0.3% in Q2 2025.